Effect of AT1727 on growth and metastasis of murine tumours.
AT1727 was tested on 5 different murine tumour systems. Compared with its analogue, razoxane, AT1727 was less effective at multiple low doses against sarcoma 180 and L1210 leukaemia. A single high-dose treatment with AT1727 was, however, more active than razoxane. AT1727 inhibited the growth of the Lewis lung primary tumour and significantly reduced the number of pulmonary metastases. Although AT1727 showed a slight inhibitory effect on the growth of the B16 primary, it had no effect on the metastases.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012510:Sarcoma 180 / Q000188:drug therapy
D000970:Antineoplastic Agents; D010879:Piperazines; C031186:bimolane; D011929:Razoxane